COMMUNIQUÉS West-GlobeNewswire

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
06/11/2025
DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will [...]
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
06/11/2025
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real [...]
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
06/11/2025
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]
Healthcare Minus the Headache: RokketMed, A Solution to Finding the Care That Counts
06/11/2025
Turnkey San Francisco Platform Aims to Help All Employers and Workers SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- In the face of mounting healthcare compliance complexity and an urgent need for accessible [...]
Raise Craze, a partnership between the MUHC Foundation, The Beat 92.5, and Pink in the City, raised $162,160 for breast cancer care at the MUHC
06/11/2025
MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) -- During October’s Breast Cancer Awareness Month, the MUHC Foundation once again partnered with The Beat 92.5 and Pink in the City, raising an extraordinary $162,160 for breast [...]
La campagne Raise Craze, un partenariat entre la Fondation du CUSM, The Beat 92.5 et Pink in the City, recueille 162,160 $ pour les soins contre le cancer du sein au CUSM
06/11/2025
MONTRÉAL, 06 nov. 2025 (GLOBE NEWSWIRE) -- Dans le cadre du Mois de la sensibilisation au cancer du sein en octobre, la Fondation du CUSM s’est de nouveau associée à The Beat 92.5 et Pink in the City. La campagne a [...]
Immunocore reports third quarter financial results and provides a business update
06/11/2025
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to [...]
ProQR Announces Third Quarter 2025 Operating and Financial Results
06/11/2025
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseases Initiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data [...]
TREOS Bio Announces Publication of Phase 1b Clinical Trial Results of PolyPEPI1018 Plus TAS-102 in Refractory MSS mCRC in JCO Oncology Advances
06/11/2025
First study to report promising activity for an active immunotherapy combined with TAS-102 (LONSURF®) in late-stage MSS mCRC; TREOS advances Phase II programme with Charité – Universitätsmedizin Berlin and Junshi [...]
American Shared Hospital Services Announces Third Quarter Financial Results Conference Call
06/11/2025
Call Scheduled for November 13 th at 1:00 PM ET SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery [...]
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
06/11/2025
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and [...]
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
06/11/2025
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage [...]
Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases
06/11/2025
Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead [...]
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
06/11/2025
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of [...]
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
06/11/2025
Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from Axsome MIAMI, [...]
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
06/11/2025
Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings [...]
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
06/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney [...]
Opus Genetics Announces $23 Million Registered Direct Offering
06/11/2025
- Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE [...]
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
06/11/2025
Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline results expected [...]

Pages